Regeneron Pharmaceuticals, Inc.
REGN
$638.88
-$3.71-0.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -5.80% | 2.52% | |||
| Total Other Revenue | -28.25% | 20.38% | |||
| Total Revenue | -7.18% | 3.46% | |||
| Cost of Revenue | 0.10% | 10.72% | |||
| Gross Profit | -16.80% | -4.78% | |||
| SG&A Expenses | -16.43% | 17.82% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | 100.00% | |||
| Total Operating Expenses | -4.19% | 12.91% | |||
| Operating Income | -17.12% | -19.04% | |||
| Income Before Tax | -20.36% | -40.81% | |||
| Income Tax Expenses | -47.76% | -34.36% | |||
| Earnings from Continuing Operations | -13.90% | -42.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -13.90% | -42.15% | |||
| EBIT | -17.12% | -19.04% | |||
| EBITDA | -16.83% | -16.28% | |||
| EPS Basic | -14.81% | -41.76% | |||
| Normalized Basic EPS | -55.97% | 61.94% | |||
| EPS Diluted | -14.09% | -42.31% | |||
| Normalized Diluted EPS | -55.58% | 60.39% | |||
| Average Basic Shares Outstanding | 1.07% | -0.68% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.28% | |||
| Dividend Per Share | 6.82% | 0.00% | |||
| Payout Ratio | 0.23% | 0.76% | |||